A personal challenge, a meaningful challenge.

The cancer

Cancer remains among the leading causes of death worldwide. This scenario urges the translation of scientific research into clinical benefits to the patients.

The treatment

New and highly effective therapies persist a challenge to be addressed. Our purpose is to improve the outcome of cancer patients by personalizing the drug delivery system.


18 million cases in 2018. 1 in 6 results in death


63 cancer drugs launching within the past five years

Global market

The global market for oncology therapeutic medicines will reach as much as $200 billion by 2022


Global oncology therapeutic medicines will average 10-13% growth over the next 5 years

Our solution

A synthetic targeted drug delivery


Personalized molecules designed to delivery treatment directly to the cancer cells

Our synthetic molecules has the potential to be more scalable, efficient and with greater specificity than those of other therapeutic classes such as cell therapy, monoclonal antibodies and small molecules, because synthetic molecules present the same level of specificity, and beside are way too simple, their production is about 20 times cheaper than the monoclonal antibodies, for example.

Selection of aptamers

Microfluid plataform

We have developed an microfluidic platform designed to select synthetic molecules capable of a range of targeted medical interventions including chemical, radiation and immunological cancer therapies. The process development and technology of our platform convert selected synthetic molecules into clinical product candidates.

Business aproach

Making science available

We develop a new class of therapies with the potential to transform the cancer treatment through precision medicine. Key elements of our strategy are to collaborate with universities, private companies and hospitals to accelerate the delivery of our technology to the patients.


Industrialize synthetic molecules to advance and scale our platform;

Intellectual property

Strengthen and expand our intellectual property to protect our platform;


Work in collaboration with universities and private companies to accelerate the development technology.


Erika Molina, Ph.D.


Emerson Moretto, M.Sc.


Advisory Board Members

Liliane Carvalho

Biominas Brazil

Eduardo Emrich

Biominas Brazil

Our partners

Supporter and Investor

Interested in partnering with Bioptamers? Contact us

   We are scientists.
Driven by curiosity.
“The important thing is to not stop questioning. Curiosity has its own reason for existing.”
Albert Einstein
   We are makers.
Driven by a problem-solve vision.
“Making is fundamental to what it means to be human.”
Mark Hatch
   We are entrepreneurs.
Driven by a problem-solve vision.
“Making the impossible inevitable.”
Michael Finnigan

Contact Us

Bioptamers, Inc.
Delaware, USA
Send us mail

Or follow us on social platform

© 2019 Bioptamers